

# NYXOAH SA NPV

ISIN: BE0974358906 WKN: B6S7WD106 Asset Class: Stock

## Company

2024/06/24 14:57:23

Price

**7.78** EUR

Difference ▼ -4.42% (-0.36)

## Contact Details

NYXOAH SA Tel: +32-10-22-23-55  
 -- Fax: +  
 Rue Edouard Belin 12 Web: <http://www.nyxoah.com>  
 1435 Mont-Saint-Guibert E-mail: [info@nyxoah.com](mailto:info@nyxoah.com)



## Company Profile

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	68,351,000		100,260,000		140,060,000	
<b>Common stock capital</b>		4,926,000		4,440,000		4,427,000
<b>Fixed assets</b>	55,806,000		45,811,000		32,087,000	
<b>Equity capital of a company</b>		98,112,000		120,334,000		149,276,000
<b>Cash and cash equivalents</b>	21,610,000		17,888,000		135,509,000	
<b>Accrued liabilities</b>		194,000		59,000		92,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		14,353,000		14,903,000		10,918,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		11,692,000		10,834,000		11,953,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		0		0		0
<b>Total assets</b>	124,157,000	124,157,000	146,071,000	146,071,000	172,147,000	172,147,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	147	138	106
<b>Equity ratio</b>	79.02%	82.38%	86.71%
<b>Debt-equity ratio</b>	26.55%	21.39%	15.32%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	3.24%	-3.89%	-12.09%

# NYXOAH SA NPV

ISIN: BE0974358906 WKN: B6S7WD106 Asset Class: Stock

## Income statement

	2023	2022	2021
<b>Turnover</b>	4,348,000	3,084,000	852,000
<b>Net income</b>	-43,212,000	-31,225,000	-27,619,000
<b>EBIT</b>	-46,021,000	-29,266,000	-23,016,000
<b>Operating income before taxes</b>	-44,657,000	-30,056,000	-24,639,000
<b>Cash Flow</b>	-45,021,000	-28,923,000	-25,729,000
<b>Net interest income</b>	1,364,000	-790,000	-1,623,000
<b>Research and development expenses</b>	25,333,000	14,843,000	4,232,000
<b>Income taxes</b>	-1,445,000	1,169,000	2,980,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	29,578	22,348	8,038

## Board of Directors

Robert Taub	Chairman of Supervisory Board
Jürgen Hambrecht	Member of Supervisory Board
Pierre Gianello	Member of Supervisory Board
Daniel Wildman	Member of Supervisory Board
Kevin Rakin	Member of Supervisory Board
Rita Johnson-Mills	Member of Supervisory Board
Virginia Kirby	Member of Supervisory Board

## Members of Management Board

Olivier Taelman	Chairman of Managing Board
An Moonen	Member of Executive Committee
Bruno Onkelinx	Member of Executive Committee
Chris Eigenmann	Member of Executive Committee
David DeMartino	Member of Executive Committee
Loic Moreau	Member of Executive Committee